HISUN(SH:600267) Mei Ri Jing Ji Xin Wen·2025-10-29 10:14Group 1 - The core point of the article is that Zhejiang Haizheng Pharmaceutical Co., Ltd. and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., participated in the 11th national centralized procurement organized by the Joint Procurement Office, with three products expected to win bids [1] - The three products that are likely to be awarded in the centralized procurement include Pravastatin Sodium Tablets, with projected sales revenue of 54.2 million yuan for the first half of 2025, Injection AdoMet, with projected sales revenue of 88.96 million yuan, and Eltrombopag Ethanolamine Tablets, with projected sales revenue of 740,000 yuan [1] - As of the report, Haizheng Pharmaceutical has a market capitalization of 13.2 billion yuan [1] Group 2 - In 2024, the revenue composition of Haizheng Pharmaceutical is expected to be: 58.46% from pharmaceutical manufacturing, 39.29% from drug sales, 1.94% from other industries, 0.23% from other businesses, and 0.08% from CMO/CDMO/CRO services [1]